Ascletis Pharma Inc. announces positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending d...
Akeso, Inc. is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from ...
Akeso Inc. (9926.HK), a leading biopharmaceutical company, has announced major advancements in its antibody drug pipeline, underscoring a transformative ...
Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neur...
Life Molecular Imaging (LMI) and St. Teresa's Hospital are pleased to announce that Florbetaben (18F) Injection (brand name: Neuraceq®) will be av...
Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...
HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license...
Akeso, Inc. ("Akeso" or the "Company") announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collabor...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clini...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of ...
Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain ...
-Vertex Pharmaceuticals Incorporated and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...
Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collective...
HUTCHMED (China) announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO&re...
© 2025 Biopharma Boardroom. All Rights Reserved.
